×
About 50,628 results

Updated COVID Boosters Offer Better Protection Than Original: US Study
https://www.medscape.com/viewarticle/984485

Nov 23rd, 2022 - (Reuters) -Updated COVID-19 boosters offer increased protection against new coronavirus subvariants in people who have previously received up to four doses of the older vaccine, based on data from the first study to assess how the retooled shots are faring in the real world, U.S. officials said on Tuesday. The findings support results from company studies showing that their updated shots produc...

FDA OKs First Gene Therapy for Hemophilia B
https://www.medpagetoday.com/hematologyoncology/hemophilia/101882

Nov 22nd, 2022 - The FDA on Tuesday approved the first gene therapy for treating hemophilia B, a genetic bleeding disorder resulting from missing or insufficient levels of factor IX. Etranacogene dezaparvovec (Hemgenix) is indicated for adults with the condition who currently use factor IX prophylaxis therapy for blood clotting, those who have or have had life-threatening hemorrhage, or those who have repeated ...

US STOCKS-Futures flat after slipping on China lockdown worries
https://www.reuters.com/article/usa-stocks/us-stocks-futures-flat-after-slipping-on-china-lockdown-worries-idUSL4N32I22S

Nov 22nd, 2022 - (For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window.) Futures: Dow up 0.09%, S&P up 0.08%, Nasdaq down 0.04% Nov 22 (Reuters) - U.S. stock index futures were trading flat on Tuesday after starting the week lower due to worries around stricter COVID-19 curbs in China, while drawing comfort from less-hawkish comments on interest-rate hikes from po...

New, Simple Technique for Chronic Subdural Hematoma Cuts Recurrence by 50%
https://www.medscape.com/viewarticle/984462

Nov 22nd, 2022 - Using irrigation warmed to body temperature during burr hole evacuation for chronic subdural hematoma (cSDH) cuts the risk for recurrence by more than half compared and should become the standard of care, new research suggests. Results from the multicenter randomized controlled trial found that irrigation at 37° C (body temperature) offered better clinical outcomes than surgery with irrigation ...

Is Bacterial Resistance the Next Pandemic? Why More Antibiotic Control (and Research) Is Needed
https://www.medscape.com/viewarticle/984121

Nov 21st, 2022 - In the past months, the political landscape in the UK has been, shall we say, tumultuous. The revolving door of Prime Ministers and Cabinet members is not compatible with a sound long-term strategy in any area controlled by the government. But one particular policy announced last month raised serious concerns for its potentially far-reaching consequences. The idea sounds reasonable on paper: En...

Are Pain Meds Bad for Your Gut?
https://www.medscape.com/viewarticle/984416

Nov 21st, 2022 - Pain is how our bodies tell us something's wrong, alerting us to injury or infection and helping doctors make a diagnosis. But pain is not fun, so we often try to block it using medication.  But a surprising new study led by Harvard Medical School researchers suggests that blocking acute pain may actually lead to pain in the gut.  That's because pain may be a key part of a process that protects...

Camsirubicin Elicits Early Clinical Activity in Advanced Soft Tissue Sarcoma
https://www.onclive.com/view/camsirubicin-elicits-early-clinical-activity-in-advanced-soft-tissue-sarcoma

Nov 18th, 2022 - The doxorubicin analogue camsirubicin in combination with pegfilgrastim (Neulasta) produced encouraging clinical activity and safety in patients with advanced soft tissue sarcoma, according to data from a phase 1b trial (NCT05043649).1 Findings showed that among 10 evaluable patients, 5 achieved stable disease at 12 weeks. The remaining 5 patients experienced progressive disease. Notably, an 1...

Atezolizumab Fails to Improve Outcomes in Postsurgery Kidney Cancer
https://www.medscape.com/viewarticle/984341

Nov 18th, 2022 - Adjuvant immunotherapy with atezolizumab for patients with renal cell carcinoma who have had a nephrectomy with or without a metastasectomy, failed to improve clinical outcomes in a group of patients who are at high risk of recurrence, finds a new international study conducted across 28 countries. The study, called IMmotion010 and published in The Lancet, was a randomized, double-blind, multice...

Ponatinib Provides Higher Rate of MRD-negative CR Vs Imatinib in Newly Diagnosed Ph+ ALL
https://www.onclive.com/view/ponatinib-provides-higher-rate-of-mrd-negative-cr-vs-imatinib-in-newly-diagnosed-ph-all

Nov 17th, 2022 - Ponatinib (Iclusig) plus reduced-intensity chemotherapy produced a higher rate of minimal residual disease (MRD)–negative complete remission compared with imatinib (Gleevec) in patients with newly diagnosed Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL), meeting the primary end point of the phase 3 PhALLCON trial (NCT03589326).1 No new safety signals with the combinat...

Ubamatamab Monotherapy Elicits Responses in Heavily Pretreated Ovarian Cancer
https://www.onclive.com/view/ubamatamab-monotherapy-elicits-responses-in-heavily-pretreated-ovarian-cancer

Nov 17th, 2022 - Ubamatamab (REGN4018) monotherapy produced early clinical activity and an acceptable risk/benefit profile in heavily pretreated patients with ovarian cancer, according to data from a phase 1 trial (NCT03564340) presented at the 2022 ESMO Congress. Findings showed that patients who received at least 1 dose of ubamatamab at 20 mg or higher (n = 42) achieved an overall response rate (ORR) of 14.3...

Could There Be a Better Treatment for MS Relapses? New Findings From Apheresis Procedures May Trigger a Guideline Update
https://www.medscape.com/viewarticle/984071

Nov 15th, 2022 - What should you do if a patient with multiple sclerosis suffers an acute relapse, but the standard methylprednisolone treatment does not result in any improvement? As it stands, the guidelines recommend a second cycle of the steroid at a double dose. A German study has now shown that visual, motor, and sensory abilities are retained better through immunoadsorption — an important finding for whe...

Moderna's Omicron Shots Shows Better Immune Response Than Original COVID Vaccine
https://www.medscape.com/viewarticle/983983

Nov 14th, 2022 - (Reuters) - Moderna Inc said on Monday its Omicron-tailored vaccines produced a better immune response against the BA.4/5 subvariants in a mid-to-late stage study, when given as a booster dose, compared with its original shot. Data shows that both of Moderna's Omicron-tailored shots, mRNA-1273.214 and mRNA-1273.222, produced a higher antibody response against BA.4/5 subvariants than its origina...

Menu19 LLC Recalls Frozen Beef Dumpling Products Produced Without Benefit of Inspection
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/732665

WASHINGTON, Nov. 9, 2022 - Menu19 LLC, a Modesto, Calif. establishment, is recalling approximately 5,001 pounds of frozen beef dumpling products that were produced without the benefit of federal inspection...

Menu19 LLC Recalls Frozen Beef Dumpling Products Produced Without Benefit of Inspection
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/732663

WASHINGTON, Nov. 9, 2022 - Menu19 LLC, a Modesto, Calif. establishment, is recalling approximately 5,001 pounds of frozen beef dumpling products that were produced without the benefit of federal inspection...

The Mind-Body Relationship in Anxiety Disorders: Therapeutic Implications
https://www.medscape.com/viewarticle/982895

Nov 11th, 2022 - Through recalling two patient experiences, Dr Sirosh Masuood considers the interactions of mind and body that ground a proper understanding of anxiety disorders, an understanding that informs effective treatment. In the first narrative, an early career encounter with a patient exposed the full complexity of addressing physical symptoms as expressions of mental disorders and prompted Masuood's c...

California Sues 3M, DuPont Over Toxic 'Forever Chemicals'
https://www.medscape.com/viewarticle/983874

Nov 11th, 2022 - (Reuters) -California's attorney general on Thursday sued 3M Co, DuPont de Nemours Inc and several other companies to recoup the "staggering" clean-up costs from toxic pollutants known as "forever chemicals." Attorney General Rob Bonta said the lawsuit followed a multiyear probe that found the companies marketed products containing polyfluoroalkyl and perfluoroalkyl substances (PFAS) for decade...

Every Patient With Metastatic Melanoma “Deserves a Shot at Nivolumab/Ipilimumab,” Weber Says
https://www.onclive.com/view/every-patient-with-metastatic-melanoma-deserves-a-shot-at-nivolumab-ipilimumab-weber-says

Nov 10th, 2022 - The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) have shown overall survival (OS) benefit in patients with metastatic melanoma, according to long-term follow-up data, and other studies’ results highlight the efficacy and toxicity benefits of different sequences of the combination, Jeffrey S. Weber, MD, PhD, said during a presentation at the 40th Annual CFS®.1 The phase 3 CheckMate...

Neoantigen TCR T-cell Therapy Shows Early Proof-of-Concept in Solid Tumors
https://www.onclive.com/view/neoantigen-tcr-t-cell-therapy-shows-early-proof-of-concept-in-solid-tumors

Nov 10th, 2022 - A personalized neoantigen-specific and off-the-shelf T cell receptor (TCR) T-cell therapy utilized through CRISPR gene editing technology demonstrated feasibility and tolerability in 16 patients across multiple tumor types, according to first-in-human phase 1a findings presented during the 2022 SITC Annual Meeting.1  Our clinical study offers early proof of concept for several steps that are...

CanSino Rolls Out Inhalable COVID Vaccine in Tianjin, Beijing
https://www.medscape.com/viewarticle/983776

Nov 10th, 2022 - BEIJING (Reuters) -Beijing residents can start making appointments for an inhalable COVID booster made by CanSino Biologics, media reported on Thursday, while those in Tianjin city can now get it as the Chinese pharmaceutical firm distributes more supplies. CanSino's vaccine, called Convidecia Air, is an aerosol version of an inactive shot and was approved as an emergency-use booster by Chinese...

First-Line AF Ablation Cuts Risk of Progression vs Drug Therapy
https://www.medscape.com/viewarticle/983882

Nov 10th, 2022 - CHICAGO – Early ablation of atrial fibrillation (AFib) reduces the risk of progression, compared with antiarrhythmic therapies, according to results of a multicenter, randomized trial called PROGRESSIVE-AF. Over 36 months of follow-up, the trial linked early ablation with a reduced risk of persistent AFib (1.9% vs. 7.4%), and in addition, those in the ablation group were less likely to have rec...